Characeteristics of relapsers and durable remitters
| Durable remitters (n=12) | Relapsers (n=10) | |
| Immunotherapy | ||
| Anti-PD-1 only | 9 | 2 |
| Combination therapy | 3 | 7 |
| Anti-CTLA-4/anti-PD-1 monotherapy or combination | 0 | 1 |
| Prior biologic therapy: | ||
| Infliximab | 4 | 9 |
| Vedolizumab | 2 | 1 |
| Mayo endoscopy score | ||
| 0 | 4 | 7 |
| 1 | 7 | 2 |
| 2 | 1 | 1 |
| Histology | ||
| Structural distortion | 2 | 1 |
| Chronic inflammatory infiltrate | 9 | 8 |
| Lamina propria neutrophils | 6 | 6 |
| Crypt abscesses | 2 | 0 |
| Erosion or ulceration | 0 | 1 |
| Apoptosis | 6 | 2 |